Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05921266 · ClinicalTrials.gov registry record · NA

Urolithin A Supplementation in Middle-aged Adults With Obesity

A NA study, sponsored by University of Oklahoma.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT05921266 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05921266, a NA study, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is: \- Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity? Participants will be asked to: * Take the dietary supplement daily for 4 weeks * Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood Researchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Urolithin A

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-10-02
Est. Completion 2025-05-14
Phase NA

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT05921266

The ClinicalTrials.gov registry entry for NCT05921266 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05921266 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05921266 about?

NCT05921266 is a clinical study titled "Urolithin A Supplementation in Middle-aged Adults With Obesity". The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is: \- Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults ...

What is the current status of trial NCT05921266?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2023-10-02. Estimated completion is 2025-05-14.

What interventions are being tested in trial NCT05921266?

The interventions under investigation include: Placebo (OTHER), Urolithin A (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05921266?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.